Kerala, WB Used ‘Extra Dose’, Reported Negative Vax Wastage

New Delhi : Exemplary performance by Kerala and West Bengal which recorded a negative (-6.3% and -5.4%) vaccine wastage, saving 1.1 lakh and 1.6 lakh doses respectively, shows that optimum use and diligent supply management of vaccines is possible, said central government officials.

In fact, the two states reported negative wastage of Covid vaccines by making use of the “extra dose” available as a wastage factor in each vial.

Official data for May show Kerala and West Bengal standing in sharp contrast to states like Jharkhand and Chhattisgarh which recorded a high 33.9% and 15.7% wastage respectively. The wastage for other states is lower, but still on the higher side like in Madhya Pradesh (7.3%) and Punjab (7%). Doing better, but still short of the optimum 1% suggested by the Centre are Delhi (3.9%), Gujarat (3.6%), Rajasthan (3.9%) and UP (3.7%).

Government sources said the closing balance of shots with various states was 212 lakh. The month saw a poor rate of vaccination due to a switch to a new procurement system — since abandoned — and a fear of infection that kept people indoors. The closing balance of vaccines was less at 80 lakh in April. However, it was higher in February and March, with the latter marked by a misplaced sense of complacency that the infection had ebbed. This had resulted in vaccination slots going unutilised.

The first dose coverage of the 45-plus population stands at 38%, with Tamil Nadu, Jharkhand, Bihar and Assam lagging at sub- 30% levels. Better performing states include Rajasthan, Chhattisgarh, Gujarat and Karnataka.

Second dose coverage among front-line workers stands at 45%, with Rajasthan, Chhattisgarh, Bengal, Kerala and MP being the better performing states. First dose coverage is at 84%. Worryingly, second dose coverage for healthcare workers is only 56% while for first dose it is 81%.

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India